When to Start Aspirin for Primary Prevention
Low-dose aspirin (75-100 mg daily) might be considered for primary prevention in select adults aged 40-70 years who have elevated ASCVD risk (≥10% 10-year risk) but are NOT at increased bleeding risk; however, aspirin should NOT be routinely used in adults over 70 years of age or in anyone with elevated bleeding risk. 1
Risk-Based Algorithm for Aspirin Initiation
Age 40-59 Years
- Consider aspirin if 10-year ASCVD risk ≥10% AND no increased bleeding risk 1, 2
- Modeling studies show positive net benefit (measured in quality-adjusted life-years) when starting in this age range at ≥5% 10-year CVD risk for men and ≥10% for women 3
- This age group shows the most favorable benefit-to-harm ratio, with number needed to treat for MACE prevention being substantially lower than in older populations 4
Age 60-69 Years
- May consider aspirin if 10-year ASCVD risk ≥10% AND no increased bleeding risk 1, 2
- Net benefits become more marginal in this age range, particularly for women 3
- The 2016 USPSTF guidelines support use in this age group when CVD risk exceeds 10% 2
Age 70+ Years
- Do NOT initiate aspirin for primary prevention 1
- This is a Class III (Harm) recommendation - meaning aspirin should not be administered routinely in this population 1
- Modeling shows lifetime net life-years are negative in most cases for persons starting aspirin between ages 60-79 years 3
- The harms (particularly bleeding) exceed benefits in this age group 4
Critical Bleeding Risk Assessment
Aspirin is contraindicated (Class III: Harm) in patients at increased bleeding risk regardless of age 1. Elevated bleeding risk includes:
- History of gastrointestinal bleeding or peptic ulcer disease
- Concurrent use of anticoagulants, NSAIDs, or corticosteroids
- Thrombocytopenia or bleeding disorders
- Uncontrolled hypertension
Dosing Specifications
When aspirin is indicated, use 75-100 mg orally daily 1, 2. Higher doses do not improve cardiovascular efficacy and increase bleeding risk 5.
Special Populations
Diabetes
The American Diabetes Association suggests aspirin for patients with diabetes who have >10% 10-year CVD risk and are not at increased bleeding risk, though they do not recommend it for most men <50 years or women <60 years with low CVD risk 2.
Elevated Lipoprotein(a)
Emerging evidence suggests individuals with elevated Lp(a) levels without established ASCVD may represent a subgroup where aspirin benefits could outweigh bleeding risks, though this remains investigational and requires prospective validation 6.
Common Pitfalls to Avoid
Do not use aspirin as a substitute for optimal risk factor management - Statin therapy, blood pressure control, smoking cessation, and lifestyle modification remain the foundation of primary prevention 1
Do not continue aspirin indefinitely without reassessing bleeding risk - The balance of benefits and harms changes with age and comorbidities 3
Do not initiate aspirin in patients over 70 - This is explicitly contraindicated in current guidelines despite historical practice patterns 1
Do not use higher doses - There is no cardiovascular benefit to doses >100 mg daily, only increased bleeding 5
Evidence Quality Considerations
The 2019 ACC/AHA guideline 1 provides the most authoritative and recent guidance, downgrading aspirin from previous recommendations. This reflects incorporation of three major contemporary trials (ARRIVE, ASCEND, ASPREE) that showed more modest benefits than earlier studies, likely due to improved background cardiovascular risk management with statins and antihypertensives. The recommendation is now Class IIb (may be considered) rather than a stronger endorsement, reflecting genuine equipoise about net benefit even in selected populations 1.
The modeling study 3 confirms that even in optimal scenarios, net benefits are concentrated in younger patients (40-59 years) with higher baseline risk, and become negative or negligible in older age groups.